Literature DB >> 14613669

Misoprostol in gynecology.

Alisa B Goldberg1, Daniela A Carusi, Karen R Meckstroth.   

Abstract

Misoprostol is an important medication for gynecologic practice; however, it is not approved by the US Food and Drug Administration for any gynecologic indication. Evidence-based practice must guide our use of this important drug. Its use for medical abortion in conjunction with mifepristone or methotrexate is supported by a large body of high-quality evidence. There is also a rapidly growing amount of literature on the use of misoprostol for the management of miscarriage; however, more research is needed to optimize use. Solid evidence supports the efficacy of misoprostol for cervical ripening before first-trimester suction curettage abortion, and good evidence supports its use before hysteroscopy in premenopausal women; however, complications are rare with these procedures, making it difficult to assess any impact on complication rates. Most studies have not demonstrated a benefit for using misoprostol as a cervical ripening agent in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613669

Source DB:  PubMed          Journal:  Curr Womens Health Rep        ISSN: 1534-5874


  4 in total

Review 1.  Interventions for pain with intrauterine device insertion.

Authors:  Laureen M Lopez; Alissa Bernholc; Yanwu Zeng; Rebecca H Allen; Deborah Bartz; Paul A O'Brien; David Hubacher
Journal:  Cochrane Database Syst Rev       Date:  2015-07-29

2.  Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design.

Authors:  K S Oppegaard; B-I Nesheim; O Istre; E Qvigstad
Journal:  BJOG       Date:  2008-01-16       Impact factor: 6.531

3.  Does self-administered vaginal misoprostol result in cervical ripening in postmenopausal women after 14 days of pre-treatment with estradiol? Trial protocol for a randomised, placebo-controlled sequential trial.

Authors:  K S Oppegaard; M Lieng; A Berg; O Istre; E Qvigstad; B-I Nesheim
Journal:  BJOG       Date:  2008-06       Impact factor: 6.531

4.  Mifepristone and Misoprostol vs Misoprostol Alone in Second Trimester Termination of Pregnancy.

Authors:  Deepa Shah; Pappu Rijal; Achala Thakur; Rubina Rai
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Sep-Oct       Impact factor: 0.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.